RXSIGHT INC (RXST)
US78349D1072 - Common Stock
We assign a fundamental rating of 4 out of 10 to RXST. RXST was compared to 188 industry peers in the Health Care Equipment & Supplies industry. While RXST seems to be doing ok healthwise, there are quite some concerns on its profitability. RXST is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
In the past year RXST has reported negative net income.
In the past year RXST has reported a negative cash flow from operations.
The reported net income has been mixed in the past 5 years: RXST reported negative net income in multiple years.
In the past 5 years RXST always reported negative operating cash flow.
1.2 Ratios
RXST has a Return On Assets of -9.89%. This is comparable to the rest of the industry: RXST outperforms 58.82% of its industry peers.
RXST has a Return On Equity of -11.07%. This is in the better half of the industry: RXST outperforms 63.10% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -9.89% | ||
| ROE | -11.07% | ||
| ROIC | N/A |
ROA(3y)-32.11%
ROA(5y)-13.87%
ROE(3y)-46.6%
ROE(5y)-4.03%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
RXST's Gross Margin of 68.44% is fine compared to the rest of the industry. RXST outperforms 78.07% of its industry peers.
RXST's Gross Margin has improved in the last couple of years.
RXST does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 68.44% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y73.04%
GM growth 5YN/A
2. Health
2.1 Basic Checks
RXST does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, RXST has more shares outstanding
Compared to 1 year ago, RXST has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 31.04 indicates that RXST is not in any danger for bankruptcy at the moment.
RXST has a Altman-Z score of 31.04. This is amongst the best in the industry. RXST outperforms 95.72% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that RXST is not too dependend on debt financing.
With a decent Debt to Equity ratio value of 0.00, RXST is doing good in the industry, outperforming 67.38% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 31.04 |
ROIC/WACCN/A
WACC9.12%
2.3 Liquidity
A Current Ratio of 12.67 indicates that RXST has no problem at all paying its short term obligations.
RXST has a better Current ratio (12.67) than 97.86% of its industry peers.
A Quick Ratio of 11.71 indicates that RXST has no problem at all paying its short term obligations.
The Quick ratio of RXST (11.71) is better than 97.33% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 12.67 | ||
| Quick Ratio | 11.71 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 60.12% over the past year.
The Revenue has grown by 67.51% in the past year. This is a very strong growth!
Measured over the past years, RXST shows a very strong growth in Revenue. The Revenue has been growing by 82.40% on average per year.
EPS 1Y (TTM)60.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)67.51%
Revenue growth 3Y82.4%
Revenue growth 5YN/A
Sales Q2Q%59.08%
3.2 Future
RXST is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 27.77% yearly.
RXST is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 26.77% yearly.
EPS Next Y37.84%
EPS Next 2Y26.71%
EPS Next 3Y24.53%
EPS Next 5Y27.77%
Revenue Next Year58.67%
Revenue Next 2Y46.34%
Revenue Next 3Y38.94%
Revenue Next 5Y26.77%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for RXST. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RXST. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
RXST's earnings are expected to grow with 24.53% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.71%
EPS Next 3Y24.53%
5. Dividend
5.1 Amount
RXST does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
RXSIGHT INC
NASDAQ:RXST (11/22/2024, 8:03:13 PM)
After market: 44.83 0 (0%)44.83
-0.22 (-0.49%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.81B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -9.89% | ||
| ROE | -11.07% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 68.44% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.41
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 12.67 | ||
| Quick Ratio | 11.71 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)60.12%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y37.84%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)67.51%
Revenue growth 3Y82.4%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y